title: Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials.
abstract: High levels of plasma lipids have been recognized as a major risk factor in the development and progression of atherosclerosis, and to influence hemorheological factors that may predispose to thrombotic complications. Lipid-lowering interventions have been associated with a significant reduction of morbidity and mortality. Several mechanisms have been postulated for the observed clinical effect. Serum lipid-regulating therapies may reduce cardiovascular risk not only by altering the arterial wall, improving disturbed endothelial function, atherogenesis and plaque stability, but also through their antithrombogenic effects and influence on blood flow properties associated with hyperlipidemia. In this article, we will review the recent literature and discuss the value of hemorheological-hemostatic findings as surrogate endpoints for clinical trials in dyslipidemic patients.
authors.affiliation: Cardiovascular Biology Research Laboratory, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, New York 10029, USA.
authors.forename: R
authors.initials: R
authors.lastname: Corti
authors.forename: J J
authors.initials: JJ
authors.lastname: Badimon
mesh_terms: D001792:Blood Platelets / Q000378:metabolism; D002624:Chemistry, Clinical; D002986:Clinical Trials as Topic; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D006949:Hyperlipidemias / Q000150:complications*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000378:metabolism; D008954:Models, Biological; D012307:Risk Factors; D013997:Time Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008074:Lipoproteins